Observational studyMuscle & nerve2026
Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.
Observational study in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
INTRODUCTION/
aimsComorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden.
methodsWe included individuals with ≥ 2 MG diagnoses (ICD codes) in nationwide health registries between 2000 and 2020 and analyzed comorbidities before and after MG diagnosis and MG-related treatments during follow-up.
resultsAmong 8819 people with MG (pwMG), 3159 were incident cases with data available ±5 years from diagnosis. Circulatory diseases were the most frequent comorbidity (19%-29%) before diagnosis, mostly explained by hypertension (13%-24%). After diagnosis, anemia and osteoporosis prevalence increased three to six fold. Mental health disorders were more frequent in younger (0-64 years) than older (≥ 65 years) pwMG. In the first year after diagnosis, acetylcholinesterase inhibitors (AChEIs) were the most used treatment in Finland (41%) and Sweden (34%), and corticosteroids (CSs) with nonsteroidal-immunosuppressive therapy (NS-IST) in Denmark (33%). By year 5, the proportion of pwMG receiving NS-IST, CS, or their combination was similar in the three countries (Denmark 47%, Finland 40%, and Sweden 41%). Only 5%-7% remained treatment-naive throughout follow-up. DISCUSSION: MG treatment was broadly similar across the three Nordic countries, while also reflecting nation-specific therapeutic guidelines. Many pwMG required multiple therapies, underscoring risks of long-term immunosuppression and highlighting the need for vigilant management and future research of safer strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.